Company Directory / Research
PrivateFor profitResearchMenlo Park, California, United States
Alladapt Immunotherapeutics
Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy.
- Founded
- 2018 8 years ago
- Staff
- 11-50 band, as listed
- Followers
- - on LinkedIn
- Funding
- $229M as listed, USD
Set against six million companies
Size
11-50 people: larger than 33% of companies with a size listed
Age
8 years old.
Reach
Website ranked #4,669,883 in the world for traffic, about 2k visits a month.
What it does
Biotechnology
What it is known for
biotechnology researchfood allergy safety profilesingle agent formulationclinical trialsoral immunotherapyfda fast trackimmune system adaptationpharmaceuticalsmulti-food allergy managementresearchadp101food allergy safety assessmentfood allergy drug candidatesupply chain managementimmune system remodelingbroad-spectrum allergy treatment
What its website runs on
Google Search ConsoleApple Business ManagerGoogle WorkspaceGoDaddy DomainsApple School ManagerGmailGoogle MeetSmartsheetZoom MeetingsAdobeGoDaddy HostingWebflow HostingDocuSignAmazon AWS
Funding, as listed
$229M raised in total
- Rounds3
- LatestDebt financing, Aug 2022
- Latest amountUSD 119,000,000
- Investors15, 3 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Alladapt Immunotherapeutics, field by field. Contact details are held but never shown.
The company
- Name
- Alladapt Immunotherapeutics
- Type
- For profit
- Status
- Private
- Founded
- 2018
- Founders
- Ashley Dombkowski, Kari Nadeau
- Industry
- Research
- Categories
- Biotechnology
Where
- City
- Menlo Park
- Region
- California
- Country
- United States
- Markets
- San Francisco Bay Area, Silicon Valley, West Coast, Western US
Size and reach
- Staff band
- 11-50
- Web traffic rank
- #4,669,883
- Monthly web visits
- 2,014
- Annual revenue
- $2.5M
Funding, as listed
- Total
- $229,000,000 USD
- Rounds
- 3
- Latest round
- Debt financing
- Latest round date
- Aug 2022
- Latest amount
- 119,000,000 USD
- Investors
- 15
- Lead investors
- 3
- Listing status
- private
Classification
- NAICS
- 54171
- SIC
- 2834
- Keywords
- 16 listed, shown above
- Technologies
- 14 detected, shown above
About this record
- Sources
- Crunchbase, Apollo
- Last imported
- Sept 2026
Growth, as the source summarises it
Alladapt Immunotherapeutics may be growing as it has received FDA Fast Track Designation for ADP101, which is a significant regulatory milestone that can expedite the development and review process for treatments of serious conditions. This designation often correlates with increased investment and interest in a company's product pipeline. Furthermore, the attention from regulatory bodies suggests that Alladapt Immunotherapeutics is advancing in its clinical development stages, which is a positive indicator of growth in the biopharmaceutical industry. The company's focus on developing treatments for food allergies, a market that is expected to register immense growth by 2032, positions it favorably within the biotechnology sector.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
Research in United States.
Rubius TherapeuticsCambridge · 1-10 people
Kemin IndustriesDes Moines · 1001-5000 peopleBBruker Cellular AnalysisEmeryville · 101-250 people
FermilabBatavia · 1001-5000 people · 96k followers
SeLux DiagnosticsBoston · 101-250 peopleFrom the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 1,637,054 companies in United States and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.